{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:27Z","timestamp":1793371527295,"version":"4.5.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.2169\/internalmedicine.6981-25","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:09:29Z","timestamp":1792015769000},"page":"2715-2719","source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib-induced Glomerular Microangiopathy after Long-term Nintedanib Administration Presenting with Nephrotic Syndrome"],"prefix":"10.2169","volume":"65","author":[{"given":"Mizuki","family":"Watada","sequence":"first","affiliation":[{"name":"Department of Nephrology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurina","family":"Yataka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Shoda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Kuyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Nagahama","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kyorin University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yarandi N, Shirali AC. Onconephrology: Core Curriculum 2023. Am J Kidney Dis 82: 743-761, 2023.","DOI":"10.1053\/j.ajkd.2023.04.014"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008.","DOI":"10.1056\/NEJMoa0707330"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: a review. Am J Kidney Dis 81: 591-605, 2023.","DOI":"10.1053\/j.ajkd.2022.10.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pfister F, Amann K, Daniel C, Klewer M, B\u00fcttner A, B\u00fcttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 73: 990-1001, 2018.","DOI":"10.1111\/his.13716"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Inoue Y, Ogura T, Azuma A, et al. Real-world safety, tolerability and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of post-marketing surveillance in Japan. Adv Ther 42: 1075-1093, 2025.","DOI":"10.1007\/s12325-024-03079-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Inoue D, Nishi H, Honda K, et al. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis. Clin Nephrol 93: 47-50, 2020.","DOI":"10.5414\/CN109900"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hasegawa M, Uehara A, Suzuki T, et al. Nintedanib-induced glomerular microangiopathy: a case report. CEN Case Rep 9: 295-300, 2020.","DOI":"10.1007\/s13730-020-00474-w"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fujita T, Nakagawa H, Yokota T, et al. Nintedanib-induced renal thrombotic microangiopathy. Case Rep Nephrol Dial 11: 227-232, 2021.","DOI":"10.1159\/000517692"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ouellet G, Picard C, Rabeyrin M, et al. Reversible glomerular thrombotic microangiopathy associated with nintedanib in a kidney transplant recipient. Kidney Int Rep 10: 2069-2070, 2025.","DOI":"10.1016\/j.ekir.2025.04.015"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003.","DOI":"10.1172\/JCI17423"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol JASN 30: 187-200, 2019.","DOI":"10.1681\/ASN.2018080853"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782, 2008.","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wind S, Schmid U, Freiwald M, et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet 58: 1131-1147, 2019.","DOI":"10.1007\/s40262-019-00766-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hanna PE, Anumolu RK, Motwani SS, et al. Risk factors for severe hypertension and proteinuria after treatment with vascular endothelial growth factor signaling pathway inhibitors among patients with cancer. Kidney Int Rep 9: 1897-1902, 2024.","DOI":"10.1016\/j.ekir.2024.03.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kiyomi A, Koizumi F, Imai S, et al. Bevacizumab-induced proteinuria and its association with antihypertensive drugs: a retrospective cohort study using a Japanese administrative database. PLoS One 18: e0289950, 2023.","DOI":"10.1371\/journal.pone.0289950"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/20\/65_6981-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:16:26Z","timestamp":1792210586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/20\/65_6981-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":15,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6981-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"6981-25"}}